Solesence vs cbdMD
SLSN and YCBD side by side, both in soap, detergents, and cleaning preparations; perfumes, cosmetics, and other toilet preparations. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SLSN and YCBD compare
Solesence is the larger company, worth 28 times as much as cbdMD ($113M against $4.1M).
cbdMD grew revenue faster over the last twelve months (10.0% versus −14.0% for Solesence).
Solesence keeps more of each dollar of sales as profit, with a net margin of −3.8% compared with −13.8% at cbdMD.
cbdMD scores higher on the StockData Score (10 against 7 for Solesence), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SLSN | YCBD |
|---|---|---|
| Size and price | ||
| Market cap | $113M | $4.1M |
| Share price | $1.60 | $0.363 |
| Change, 1 year | −2.4% | −50.8% |
| Change, 5 years | −57.1% | −99.9% |
| Beta (5Y) | 3.79 | 2.28 |
| Employees | 115 | 42 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.0× | 0.2× (better) |
| P/B | 8.6× | 0.5× (better) |
| FCF yield | – | −59.2% |
| Fair value | $1.68 | $2.01 |
| Margin of safety | 5.0% | 82.0% (better) |
| Growth | ||
| Revenue growth (TTM) | −14.0% | 10.0% (better) |
| Revenue growth, 5Y average | 29.4% (better) | −14.5% |
| Net income growth (TTM) | −134% | – |
| EPS growth (TTM) | −143% | – |
| EPS growth, 5Y average | −7.8% | – |
| Profitability | ||
| Gross margin | 26.5% | 57.7% (better) |
| Operating margin | −2.1% (better) | −13.9% |
| Net margin | −3.8% (better) | −13.8% |
| FCF margin | – | −11.5% |
| Return on equity | −15.1% (better) | −40.3% |
| Return on invested capital | −8.3% (better) | −41.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.97 | 2.50 (better) |
| Altman Z-score | 0.01 (better) | −17.59 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.09% | – |
| Shareholder yield | −0.09% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 4.5% | 8.2% |
| Held by insiders | 75.2% | 34.6% |
| Insider net buying, 12 months | $4.8K (better) | −$1.3M |
| Short interest, % of float | 2.1% | 6.6% |
Go deeper
- SLSN stock overview
- SLSN income statement
- SLSN valuation and score
- YCBD stock overview
- YCBD income statement
- YCBD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.